Foresee Pharmaceuticals Announces Successful Topline Results from Phase 3 Registration Study of LMIS 25 mg in Prostate Cancer
TAIPEI, Taiwan, February 21, 2…
The Art & Science of Wellness
BEIJING, Feb. 20, 2019 /PRNews…
WATERFORD, Wisconsin, Feb. 20,…
Transformational Health expert…
– Proxy-CRISPR technolog…
COPENHAGEN, Denmark and AMSTER…
-Earnings Call Scheduled for 8…
New Company to be called ̶…
多語言WordPress ,採用WPML